Hit enter to search or ESC to close

News

Alterity’s lead drug candidate receives positive opinion from European medical agency

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on recommending the designation of its lead molecule PBT434 for the treatment of Multiple System Atrophy (MSA) as an orphan medicinal product to the European Commission (EC). Following ...

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Nice, France. The poster will present findings from the completed ...

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Janney Healthcare Conference in New York 9-10th September. The event will be attended by major US and European institutional investors, as well as Janney’s largest private client advisors. Dr David Stamler, Alterity’s Chief Medical Officer, will be presenting at the ...

Quarterly Cash Flow Report

Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations in the brain comparable with other test results   Presentation of clinical trial data at the American Academy of Neurology Life Biosciences leads investment round raising an initial A$11.44M during the quarter Name change to Alterity ...

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully completed its Phase 1 study of PBT434, a novel, orally bioavailable small molecule inhibitor of alpha-synuclein aggregation. Alpha-synuclein, when aggregated in the brain, is a pathological hallmark of Parkinsonian conditions and is considered an important biologic target for ...

Alterity AGM Investor Conference Call

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference. The AGM is scheduled for 9:30 AM (Australian Eastern Daylight Time) Tuesday, November 26th, 2019 at the Adina Apartment Hotel, 189 Queen Street, Melbourne. Registration is from 9:15 AM. To ...

Quarterly Cash Flow Report

Highlights: Results of Phase 1 Clinical Trials for lead compound PBT434 announced Presentation of clinical trial data at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in France Presentation at the Janney Healthcare conference in New York Cash balance of $10.7M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the ...

Receive news from Alterity Therapeutics